Site icon Impactiviti

Impactiviti Daily 093009


Novartis’ new MS drug (FTY 720) looking good in Phase III trials. New results just released.

Vertextakeover target? For a company looking to expand into Hepatitis C, Vertex is a prime candidate.

Boston Scientific and J&J making peace with the lawyer-enriching stent suits.


Call center/phone rep training. The Impactiviti Partner Network has great providers to help you with this need. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.


Careful of those press releases, pharma execs. They could land you in jail! Of course, mishandling data can get you publicly fired. And, from bNet Pharma, the 10 weirdest drug stories of the month.


Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Exit mobile version